Advertisement
Advertisement


The Body PRO Covers: The 8th Conference on Retroviruses and Opportunistic Infections

Antiretroviral Switch Studies for Metabolic Complications

February 7, 2001

  • Metabolic and Clinical Evaluation of Lipodystrophy Syndrome (LD) in HIV-1-Infected Adults Receiving Initial HAART with or without a Protease Inhibitor (PI): 48-Week Data from the CNAF3007 Study (Poster 670)
    Authored by Authored by S. Matheron, P. Massip, C. Trepo, G. Lepeu, J. F. Delfraissy, J. A. Gastaut, A. Goetsche, and J. P. Mamet on behalf of the CNAF3007 Study Group
    View the original abstract


In the CNAF3007 study abacavir (n=96) versus nelfinavir (n=92) in combination with AZT/3TC was compared. A poster presented by Matheron and colleagues examined metabolic and body fat parameters at 48 weeks. The 48-week virologic results found that 65% of the abacavir and 61% of the nelfinavir group had plasma RNA <50 copies/mL (no significant difference). The cholesterol level increased significantly more in the nelfinavir arm while the greater triglyceride increase in the nelfinavir was not statistically significant. Both groups had a small increase in glucose levels. Six patients in the abacavir arm and eleven patients in the nelfinavir arm were reported to develop fat redistribution by 48 weeks (not statistically different). The excess cases in the nelfinavir group consisted of lipoatrophy and venous abnormalities in the legs.


Previous | Next


This article was provided by TheBodyPRO.com. It is a part of the publication The 8th Conference on Retroviruses and Opportunistic Infections.
 



Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.
Advertisement